Global Oligonucleotide CDMO Market Size study & Forecast, by Application (Pharmaceuticals, Biotechnology, Research, Diagnostics, Gene Therapy) and Type (DNA, RNA, siRNA, mRNA, Antisense Oligonucleotides) and Regional Forecasts 2025-2035

Description

The Global Oligonucleotide CDMO Market, currently valued at approximately USD 0.82 billion in 2024, is set to witness a striking CAGR of 16.00% from 2025 to 2035, underpinned by the growing demand for precision medicine, the rise of genetic therapies, and the surging pipeline of nucleic acid-based drug candidates. As the pharmaceutical and biotechnology sectors race to harness oligonucleotides for targeted therapies, the need for specialized contract development and manufacturing organizations (CDMOs) has intensified. These partners provide advanced synthesis capabilities, stringent regulatory compliance, and scalable production-key elements for bringing novel genetic treatments from concept to clinic. The market's momentum is further fueled by rapid advancements in automated synthesis platforms, purification technologies, and analytical tools that enable high-purity, clinical-grade oligonucleotide manufacturing at unprecedented speeds.

The proliferation of RNA-based vaccines, antisense therapeutics, and small interfering RNA (siRNA) treatments has redefined the therapeutic landscape, driving CDMOs to expand capacity and diversify service portfolios. According to industry insights, more than 500 oligonucleotide-based drug candidates are currently in various stages of clinical development, with a significant portion targeting rare diseases and oncology indications. This surge in R&D activity, coupled with the increasingly complex chemistry involved in manufacturing diverse oligonucleotide types-including DNA, RNA, mRNA, siRNA, and antisense molecules-has created an urgent need for CDMOs that can deliver end-to-end solutions. Moreover, collaborations between biotech innovators and CDMOs are not merely transactional but strategic, often involving co-development agreements that accelerate time-to-market. However, challenges such as high production costs, limited availability of skilled personnel, and stringent regulatory hurdles may temper growth trajectories in certain regions over the forecast period.

From a regional perspective, North America is expected to maintain a commanding position in the global oligonucleotide CDMO space, bolstered by a robust biotech ecosystem, significant venture capital inflows, and an advanced regulatory framework that supports innovation while ensuring patient safety. Europe follows closely, driven by strong research networks, government-backed funding for genetic medicine, and a growing cluster of specialized manufacturing facilities in countries such as Germany, the UK, and Switzerland. Meanwhile, the Asia Pacific region is projected to register the fastest CAGR, propelled by cost-effective manufacturing capabilities, an expanding pool of skilled scientists, and strategic investments in biotechnology infrastructure across China, India, and South Korea. With increasing government support for genomic research and a rising number of local biopharma startups, the region is poised to emerge as both a manufacturing hub and a significant consumer market for oligonucleotide therapeutics.

Major market player included in this report are:

Thermo Fisher Scientific Inc.
Lonza Group AG
WuXi AppTec Co., Ltd.
Eurofins Scientific SE
Merck KGaA
Agilent Technologies, Inc.
Syngene International Ltd.
Bio-Synthesis Inc.
Bachem Holding AG
Integrated DNA Technologies, Inc.
LGC Biosearch Technologies
Sarepta Therapeutics, Inc.
Nitto Denko Avecia Inc.
GeneDesign, Inc.
TriLink BioTechnologies, LLC

Global Oligonucleotide CDMO Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Application:

Pharmaceuticals
Biotechnology
Research
Diagnostics
Gene Therapy

By Type:

DNA
RNA
siRNA
mRNA
Antisense Oligonucleotides

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Oligonucleotide CDMO Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings

Chapter 3. Global Oligonucleotide CDMO Market Forces Analysis

3.1. Market Forces Shaping The Global Oligonucleotide CDMO Market (2024-2035)
3.2. Drivers
- 3.2.1. Rapid rise in oligonucleotide therapeutics (mRNA, siRNA, antisense) and outsourcing trend among biopharma
- 3.2.2. Increasing clinical pipelines for gene therapies and need for GMP-grade custom synthesis capacity
3.3. Restraints
- 3.3.1. High capital and operating expenditure for GMP manufacturing and complex purification processes
- 3.3.2. Stringent regulatory requirements and raw-material/supply chain constraints for oligonucleotide building blocks
3.4. Opportunities
- 3.4.1. Strategic CDMO-biotech collaborations, capacity expansions and regional manufacturing hubs (APAC)
- 3.4.2. Technological advances in automated synthesis, scalable purification and analytics enabling cost efficiencies

Chapter 4. Global Oligonucleotide CDMO Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Oligonucleotide CDMO Market Size & Forecasts by Type 2025-2035

5.1. Market Overview
5.2. Global Oligonucleotide CDMO Market Performance - Potential Analysis (2025)
5.3. DNA
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. RNA
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. siRNA
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. mRNA
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035
5.7. Antisense Oligonucleotides
- 5.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.7.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Oligonucleotide CDMO Market Size & Forecasts by Application 2025-2035

6.1. Market Overview
6.2. Global Oligonucleotide CDMO Market Performance - Potential Analysis (2025)
6.3. Pharmaceuticals
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Biotechnology
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Research
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Diagnostics
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035
6.7. Gene Therapy
- 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.7.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Oligonucleotide CDMO Market Size & Forecasts by Region 2025-2035

7.1. Oligonucleotide CDMO Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Oligonucleotide CDMO Market
- 7.3.1. U.S. Oligonucleotide CDMO Market
  - 7.3.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.1.2. Application breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Oligonucleotide CDMO Market
  - 7.3.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.2.2. Application breakdown size & forecasts, 2025-2035
7.4. Europe Oligonucleotide CDMO Market
- 7.4.1. UK Oligonucleotide CDMO Market
  - 7.4.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.1.2. Application breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Oligonucleotide CDMO Market
  - 7.4.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.2.2. Application breakdown size & forecasts, 2025-2035
- 7.4.3. France Oligonucleotide CDMO Market
  - 7.4.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.3.2. Application breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Oligonucleotide CDMO Market
  - 7.4.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.4.2. Application breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Oligonucleotide CDMO Market
  - 7.4.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.5.2. Application breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Oligonucleotide CDMO Market
  - 7.4.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.6.2. Application breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Oligonucleotide CDMO Market
- 7.5.1. China Oligonucleotide CDMO Market
  - 7.5.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.1.2. Application breakdown size & forecasts, 2025-2035
- 7.5.2. India Oligonucleotide CDMO Market
  - 7.5.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.2.2. Application breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Oligonucleotide CDMO Market
  - 7.5.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.3.2. Application breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Oligonucleotide CDMO Market
  - 7.5.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.4.2. Application breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Oligonucleotide CDMO Market
  - 7.5.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.5.2. Application breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Oligonucleotide CDMO Market
  - 7.5.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.6.2. Application breakdown size & forecasts, 2025-2035
7.6. Latin America Oligonucleotide CDMO Market
- 7.6.1. Brazil Oligonucleotide CDMO Market
  - 7.6.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.1.2. Application breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Oligonucleotide CDMO Market
  - 7.6.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.2.2. Application breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Oligonucleotide CDMO Market
- 7.7.1. UAE Oligonucleotide CDMO Market
  - 7.7.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.1.2. Application breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Oligonucleotide CDMO Market
  - 7.7.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.2.2. Application breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Oligonucleotide CDMO Market
  - 7.7.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.3.2. Application breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Thermo Fisher Scientific Inc.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Lonza Group AG
8.4. WuXi AppTec Co., Ltd.
8.5. Eurofins Scientific SE
8.6. Merck KGaA
8.7. Agilent Technologies, Inc.
8.8. Syngene International Ltd.
8.9. Bio-Synthesis Inc.
8.10. Bachem Holding AG
8.11. Integrated DNA Technologies, Inc.
8.12. LGC Biosearch Technologies
8.13. Sarepta Therapeutics, Inc.
8.14. Nitto Denko Avecia Inc.
8.15. GeneDesign, Inc.
8.16. TriLink BioTechnologies, LLC